Gossamer Bio (GOSS) Financial statements
Gossamer Bio reported revenue of $48M in fiscal 2025, down 57.7% a year over 1 years.
Key figures
Net income was -$170M. Free cash flow was -$171M. The diluted share count rose 2395% over the period (dilution).
- Revenue, FY2025
- $48M-57.7% on 2024
- Net income
- -$170M+201.4% on 2024
- Operating margin
- -352.2%
- Free cash flow
- -$171M+4840.7% on 2024
Revenue and free cash flow
Fiscal years, from Gossamer Bio's 10-K filings.
Gossamer Bio revenue and free cash flow
FY2017–FY2025Margins
How much of each dollar of revenue is left after the cost of sales, after operating costs, and at the bottom line.
Gossamer Bio margins
FY2017–FY2025Financial statements
Fiscal 2017–2025.
Gossamer Bio income statement, fiscal 2017–2025
| USD | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $115M | $48M |
| Research and development | $891,000 | $55M | $143M | $161M | $170M | $171M | $135M | $138M | $174M |
| Selling, general and admin | $262,000 | $44M | $39M | $50M | $46M | $48M | $38M | $36M | $38M |
| Operating income | -$7M | -$149M | -$186M | -$234M | -$216M | -$219M | -$184M | -$60M | -$171M |
| Interest expense | — | $12,000 | $2M | $13M | $19M | $14M | $14M | $12M | $11M |
| Pre-tax income | $7M | -$147M | -$180M | -$243M | -$234M | -$229M | -$180M | -$56M | -$170M |
| Income tax | $0 | $0 | $0 | — | — | $0 | $0 | $893,000 | -$88,000 |
| Net income | -$7M | -$147M | -$180M | -$243M | -$234M | -$229M | -$180M | -$57M | -$170M |
| EPS (diluted) | -$0.74 | -$22.59 | -$3.29 | -$3.55 | -$3.13 | -$2.71 | -$1.18 | -$0.25 | -$0.75 |
| Diluted shares | 9M | 7M | 55M | 69M | 75M | 85M | 153M | 226M | 229M |
| Operating margin | — | — | — | — | — | — | — | -52.2% | -352.2% |
| Net margin | — | — | — | — | — | — | — | -49.3% | -351.5% |
Gossamer Bio balance sheet, fiscal 2017–2025
| USD | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $315,000 | $229M | $402M | $513M | $325M | $256M | $296M | $295M | $137M |
| Receivables | — | — | — | — | — | — | $0 | $5M | $12M |
| Total current assets | — | $232M | $409M | $522M | $332M | $262M | $307M | $310M | $168M |
| Property, plant and equipment | — | $3M | $5M | $6M | $5M | $4M | $2M | $10,000 | $64,000 |
| Total assets | — | $239M | $427M | $539M | $344M | $272M | $312M | $315M | $172M |
| Total current liabilities | — | $20M | $37M | $39M | $40M | $49M | $52M | $45M | $63M |
| Long-term debt | — | $0 | $28M | $29M | $29M | $12M | $814,000 | $0 | — |
| Total liabilities | — | $21M | $74M | $219M | $222M | $260M | $249M | $286M | $295M |
| Shareholders' equity | -$7M | -$120M | $352M | $321M | $121M | $12M | $63M | $29M | -$123M |
| Net debt | -$315,000 | -$105M | -$107M | -$457M | -$154M | -$88M | -$20M | -$46M | -$38M |
Gossamer Bio cash flow, fiscal 2017–2025
| USD | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6M | -$51M | -$145M | -$176M | -$189M | -$187M | -$159M | -$3M | -$171M |
| Capital spending | — | $3M | $3M | $2M | $2M | $410,000 | $0 | $0 | $79,000 |
| Free cash flow | — | -$55M | -$148M | -$178M | -$190M | -$187M | -$159M | -$3M | -$171M |
| Stock-based compensation | $32,000 | $31M | $21M | $39M | $32M | $43M | $29M | $21M | $11M |
| Net borrowing | — | — | $28M | $0 | $0 | -$6M | -$12M | -$13M | $0 |
| Free cash flow margin | — | — | — | — | — | — | — | -3.0% | -353.5% |
How Gossamer Bio compares
Gossamer Bio's operating margin is higher than 13% of Healthcare companies and 5% of the 2,822 companies with an operating margin figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Operating margin | 13% | 5% |
| Net margin | 15% | 5% |
| Revenue growth | 77% | 85% |
Questions about Gossamer Bio
What was Gossamer Bio's revenue in 2025?
$48M in fiscal 2025, from its 10-K filing.
How much free cash flow does Gossamer Bio generate?
-$171M in fiscal 2025 (operating cash flow minus capital spending).
From Gossamer Bio's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.